Glycine, NAC and GlyNAC: what changed in humans?
In this investigation
A separate question from collagen
I previously took glycine and collagen, and I prefer broth to collagen powder. That history does not establish a current supplement dose or a missing amino acid. The collagen investigation covers the small glycine sleep experiment and broth’s uncertain composition.
GlyNAC combines glycine with N-acetylcysteine (NAC), a modified cysteine preparation. Collagen or broth does not reproduce that combination. The question here is whether these particular supplements improved human function, rather than whether their ingredients participate in a useful biochemical pathway.
Where the older-adult signal began
A 2021 open-label pilot followed eight adults aged 71–80 during 24 weeks of GlyNAC capsules and 12 weeks after stopping. Eight young adults supplied baseline comparisons and received no supplementation. Walking, strength and several cognitive scores improved during treatment; some changes receded after withdrawal. All participants completed the study.
Without a blinded older-adult placebo group, these observations cannot separate supplementation from time, expectations or repeated testing. The many P values were explicitly unadjusted for multiplicity. This was a reason to run a controlled trial, not proof of rejuvenation or benefit for young lifters. Kumar and colleagues, 2021
What the randomized trial adds—and leaves open
The trial randomized 24 older adults to GlyNAC or author-described isonitrogenous alanine capsules for 16 weeks; 11 and 12 completed. GlyNAC supplied 100 mg/kg/day each of glycine and NAC.
Muscle glutathione is the current registry’s primary outcome. It increased; gait, grip and chair-rise improved within the GlyNAC group. Functional tables emphasize within-group changes: improvement in one arm and nonsignificance in another do not establish a treatment difference. Six-minute-walk change was P=.053; lean mass did not significantly change.
Holm correction covered comparisons within each measurement. Aging-hallmark assays were added after completion; some used three participants per group. A young group received two weeks without placebo. NIH/philanthropic funders were reported uninvolved; authors declared no conflicts. This does not demonstrate lifespan extension. Original trial, online in 2022
The larger trial that missed its main endpoint
Another trial randomized 117 generally healthy older adults, with 114 completing, to 14 days of placebo or total daily GlyNAC doses of 2.4, 4.8 or 7.2 g, equally divided between glycine and NAC. Its primary endpoint—whole-blood total glutathione—did not significantly improve at any dose versus placebo. Neither did the reduced-to-oxidized glutathione ratio.
A favorable low-glutathione/high-oxidative-stress subset came from post-hoc analysis, not a successful primary endpoint. Shorter duration, lower exposure and different measurements limit comparison with Baylor. The null result does not settle other protocols. Nestlé employees authored the study; the disclosure identifies commercial patents/products. Registration followed the reported study period. Lizzo and colleagues, 2022, current registry
NAC and exercise do not give a simple recovery rule
In a small crossover experiment, 10 men received NAC or placebo during eight days after 300 eccentric contractions. NAC reduced some inflammatory markers and the early loss of strength, yet the original abstract reports complete performance recovery only with placebo. Better-looking early markers did not guarantee better later recovery. This was severe experimental muscle damage, not my ordinary low-set lifting session, an injured shoulder or a long-term hypertrophy trial.
The original abstract and indexed methods were accessible; full published methods and supplement files were not. The registry was posted after study completion and lists muscle function as secondary. The result warrants caution about the endpoint being optimized, without proving that all NAC use impairs adaptation. Michailidis and colleagues, 2013
Two reports from the same 2026 NAC project
A July biochemical report and September accepted performance manuscript describe 108 randomized and 77 analyzed participants, with the same registry, dates, flow and baseline characteristics. They represent one cohort, not independent replications, using 1.2 g/day NAC in seven-day crossover periods.
Homocysteine fell; reduced glutathione did not significantly change. The primary 60-minute distance result was null; selected male perceived-effort, heart-rate and Wingate-average-power findings were positive. Female peak-power genotype interactions yielded no significant pairwise effects.
Wingate preceded the time trial by 20 minutes. Exploratory subgroups, multiple endpoints and uncontrolled training limit interpretation. Registration followed recruitment’s start; historical prespecification remains unestablished. July names biochemical primaries while the current registry lists performance. Authors declared no conflicts; only July describes publication-cost funding. July biochemical report, September accepted manuscript.
Does this change my daily shopping?
These studies establish no extra purchase or personal anti-aging protocol for my routine. None tested treating my shoulder.